Kamada Ltd (KMDA) — 6-K Filings

6-K Filings (33)

• 6-K Filing — May 6, 2026
• Kamada Ltd. Updates Dividend Withholding Tax Procedures — Mar 31, 2026 Risk: low
  Kamada Ltd. announced on March 31, 2026, an update regarding withholding tax procedures for its previously announced cash dividend. The company is providing inf
• KAMADA: FDA APPROVES SAN ANTONIO PLASMA COLLECTION CENTER — Mar 26, 2026
  Kamada Ltd. announced on March 26, 2026, that the U.S. Food and Drug Administration (FDA) has approved its new plasma collection center located in San Antonio,
• Kamada Ltd. Extends Canadian Supply Tender by $10-14M — Dec 18, 2025 Risk: low
  Kamada Ltd. announced on December 18, 2025, an extension of a Canadian supply tender valued between $10 million and $14 million. This filing incorporates the an
• Kamada Ltd. Holds Annual Shareholder Meeting — Dec 10, 2025 Risk: low
  On December 10, 2025, Kamada Ltd. held its Annual General Meeting of Shareholders in Rehovot, Israel. Shareholders voted on and approved matters presented at th
• Kamada Discontinues Phase 3 Trial, Still Eyes 2026 Growth — Dec 8, 2025 Risk: medium
  Kamada Ltd. announced on December 8, 2025, the discontinuation of its Phase 3 clinical trial for inhaled Alpha-1 Antitrypsin (AAT). Despite this setback, the co
• Kamada Ltd. Files 6-K with Q3 & 9-Month 2025 Results — Nov 10, 2025 Risk: low
  Kamada Ltd. filed a Form 6-K on November 10, 2025, reporting its strong third quarter and nine-month results for 2025. This report is incorporated by reference
• 6-K Filing — Nov 4, 2025
• Kamada Ltd. Sets December 10th Annual Shareholder Meeting — Oct 23, 2025 Risk: low
  Kamada Ltd. announced on October 23, 2025, that its Annual General Meeting of Shareholders will be held on Wednesday, December 10, 2025, at 4:00 p.m. Israel tim
• Kamada Ltd. to Attend September Investor Conferences — Sep 2, 2025 Risk: low
  Kamada Ltd. announced on September 2, 2025, that it will participate in upcoming investor conferences throughout September 2025. The company is a foreign privat
• Kamada Ltd. Reports Strong Q2 and H1 2025 Financial Results — Aug 13, 2025 Risk: low
  Kamada Ltd. reported strong financial results for the second quarter and first half of 2025. The company filed a Form 6-K on August 13, 2025, to incorporate the
• Kamada Ltd. Secures FDA Approval for Houston Plasma Center — Aug 11, 2025 Risk: low
  Kamada Ltd. announced on August 11, 2025, that it has received FDA approval for its plasma collection center located in Houston, Texas. This approval is a signi
• Kamada Ltd. to Report Q2 2025 Financials Aug 13 — Aug 6, 2025 Risk: low
  Kamada Ltd. is filing a Form 6-K to announce its second quarter and first half financial results for the period ending June 30, 2025. The company will host a co
• Kamada Ltd. Confirms Global Operations and Product Availability — Jun 17, 2025 Risk: low
  Kamada Ltd. filed a Form 6-K on June 17, 2025, to confirm its continuous global business operations and product availability. This report is being incorporated
• Kamada Ltd. Files Q1 2025 Results, Incorporates into S-8 Filings — May 14, 2025 Risk: low
  Kamada Ltd. reported strong first quarter 2025 financial results for the period ending March 31, 2025. The company is incorporating this Form 6-K filing into se
• Kamada Ltd. to Report Q1 2025 Results on May 14 — May 7, 2025 Risk: low
  Kamada Ltd. announced on May 7, 2025, that it will report its first quarter 2025 financial results on May 14, 2025. This Form 6-K filing is being incorporated b
• Kamada Launches Post-Marketing Research for CYTOGAM — May 5, 2025 Risk: low
  Kamada Ltd. announced on May 5, 2025, the launch of a comprehensive post-marketing research program for its product CYTOGAM. This report is being incorporated b
• Kamada Ltd. Updates on Dividend Tax Procedures — Mar 24, 2025 Risk: low
  Kamada Ltd. filed a Form 6-K on March 24, 2025, to provide an update on withholding tax procedures related to a previously announced special cash dividend to sh
• Kamada Ltd. Expands Plasma Collection with New Texas Site — Mar 19, 2025 Risk: low
  Kamada Ltd. announced on March 19, 2025, the expansion of its plasma collection operations with the opening of a new site in San Antonio, Texas. This expansion
• Kamada Ltd. to Report Q4 & FY2024 Results March 5 — Feb 26, 2025 Risk: low
  Kamada Ltd. announced on February 26, 2025, that it will report its fourth quarter and fiscal year 2024 financial results on March 5, 2025. This Form 6-K filing
• Kamada Secures $25M Latin America Supply Deal — Jan 22, 2025 Risk: medium
  Kamada Ltd. announced on January 22, 2025, a new 3-year contract worth $25 million for the supply of its KAMRAB® and VARIZIG® products in Latin America. This ag
• Kamada Ltd. Affirms 2024 Guidance, Eyes Double-Digit Growth in 2025 — Jan 8, 2025 Risk: low
  Kamada Ltd. filed a Form 6-K on January 8, 2025, incorporating by reference its financial guidance for 2024 and announcing expectations for continued double-dig
• Kamada Ltd. Holds Annual Shareholder Meeting — Dec 11, 2024 Risk: low
  On December 11, 2024, Kamada Ltd. held its Annual General Meeting of Shareholders in Rehovot, Israel. Shareholders voted on and approved matters presented at th
• Kamada Ltd. Reports Profitable Growth in Q3 2024 — Nov 13, 2024 Risk: low
  Kamada Ltd. reported strong third quarter and nine-month results for 2024, indicating continued profitable growth. The company is a foreign private issuer filin
• Kamada Ltd. to Report Q3 2024 Financials Nov 13 — Nov 6, 2024 Risk: low
  Kamada Ltd. announced it will report its financial results for the third quarter and nine months ended September 30, 2024, on November 13, 2024. This Form 6-K f
• Kamada Ltd. to Present at Stifel Healthcare Conference — Nov 4, 2024 Risk: low
  Kamada Ltd. announced on November 4, 2024, that it will present at the Stifel 2024 Healthcare Conference. This Form 6-K filing is being incorporated by referenc
• Kamada Ltd. Sets Shareholder Meeting for Dec 11 — Oct 21, 2024 Risk: low
  Kamada Ltd. announced its Annual General Meeting of Shareholders will be held on Wednesday, December 11, 2024, at 4:00 p.m. Israel time. The meeting will take p
• Kamada Ltd. Opens New Plasma Collection Site in Houston — Sep 23, 2024 Risk: low
  Kamada Ltd. announced on September 23, 2024, the expansion of its plasma collection operations in Texas with the opening of a new site in Houston. This expansio
• Kamada Ltd. Reports Strong Q2 & H1 2024 Financials — Aug 14, 2024 Risk: low
  Kamada Ltd. reported strong financial results for the second quarter and first half of 2024. The company experienced an 18% year-over-year increase in its top-l
• Kamada Ltd. to Report Q2 2024 Financials August 14 — Aug 7, 2024 Risk: low
  Kamada Ltd. announced on August 7, 2024, that it will report its financial results for the second quarter and first half ended June 30, 2024, on August 14, 2024
• Kamada Ltd. Q1 2024 Results: 23% Revenue Growth, 96% Profitability Jump — May 8, 2024 Risk: medium
  Kamada Ltd. reported strong first quarter 2024 financial results, with a 23% year-over-year increase in revenue and a 96% increase in profitability. The company
• Kamada Ltd. to Report Q1 2024 Results on May 8 — May 1, 2024 Risk: low
  Kamada Ltd. announced on May 1, 2024, that it will release its first quarter 2024 financial results on May 8, 2024. This announcement is being made via a Form 6
• Kamada to Announce Q4/FY23 Results & 2024 Guidance March 6 — Feb 28, 2024 Risk: low
  Kamada Ltd. announced on February 28, 2024, that it will release its fourth quarter and fiscal year 2023 financial results on March 6, 2024. The company will al

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX